CD19/22 Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 60
- sponsor
- Shenzhen Geno-Immune Medical Institute
- conditions
- B Cell Malignancies
- interventions
- BIOLOGICAL: bi-4SCAR CD19/22 T cells
- start date
- 2027-06-01
- start date type
- ESTIMATED
- primary completion date
- 2029-12-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05432882
- Published
- Jun 27, 2022
- Updated
- Aug 26, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05432882
- Categories
- B Cell Malignancies
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials